Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Pemvidutide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Altimmune eyes phase 3 MASH trial as weight loss deepens
    Altimmune eyes phase 3 MASH trial as weight loss deepens

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208385/0/en/Altimmune-Announces-that-Pemvidutide-Achieved-Key-Measures-of-Success-at-48-Weeks-in-IMPACT-Phase-2b-MASH-Trial.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb
    Altimmune Poised For $1B+ Opportunity As MASH Drug Aces Phase IIb

    13 Nov 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/altimmune-poised-for-1b-opportunity-as-mash-drug-aces-phase-iib

    BIOSPACE
    13 Nov 2025
    Share Share
    Altimmune Announces Publication of IMPACT Phase 2b Trial Data
    Altimmune Announces Publication of IMPACT Phase 2b Trial Data

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185445/0/en/Altimmune-Announces-Publication-of-IMPACT-Phase-2b-Trial-Data-in-The-Lancet-and-Concurrent-Late-Breaking-Oral-Presentation-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b
    Altimmune Show AI-Based Liver Fibrosis Data From Pemvidutide Ph2b

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183618/0/en/Altimmune-Presents-AI-Based-Analysis-of-Liver-Fibrosis-Reduction-from-IMPACT-Phase-2b-Trial-of-Pemvidutide-in-MASH-in-Late-breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Metavia To Unveil DA-1726 Phase 1 Data At Obesityweek 2025
    Metavia To Unveil DA-1726 Phase 1 Data At Obesityweek 2025

    05 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-to-present-new-phase-1-and-pre-clinical-data-on-da-1726-at-obesityweek-2025-302604527.html

    PR NEWSWIRE
    05 Nov 2025
    Share Share
    Altimmune To Present Phase 2B Pemvidutide Data In MASH At AASLD
    Altimmune To Present Phase 2B Pemvidutide Data In MASH At AASLD

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169260/0/en/Altimmune-to-Present-Phase-2b-IMPACT-Data-on-Pemvidutide-in-MASH-in-Late-Breaking-Oral-Podium-Presentation-and-Late-Breaking-Poster-at-AASLD-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.